BRIM Biotechnology Inc.
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing B… Read more
Market Cap & Net Worth: BRIM Biotechnology Inc. (6885)
BRIM Biotechnology Inc. (TWO:6885) has a market capitalization of $118.39 Million (NT$3.92 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #18778 globally and #894 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BRIM Biotechnology Inc.'s stock price NT$29.85 by its total outstanding shares 131225000 (131.22 Million).
BRIM Biotechnology Inc. Market Cap History: 2022 to 2025
BRIM Biotechnology Inc.'s market capitalization history from 2022 to 2025. Data shows growth from $151.31 Million to $118.39 Million (5.73% CAGR).
BRIM Biotechnology Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BRIM Biotechnology Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1306.63x
BRIM Biotechnology Inc.'s market cap is 1306.63 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $151.31 Million | $526.00K | -$274.28 Million | 287.66x | N/A |
| 2023 | $117.60 Million | $90.00K | -$688.02 Million | 1306.63x | N/A |
Competitor Companies of 6885 by Market Capitalization
Companies near BRIM Biotechnology Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to BRIM Biotechnology Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BRIM Biotechnology Inc. Historical Marketcap From 2022 to 2025
Between 2022 and today, BRIM Biotechnology Inc.'s market cap moved from $151.31 Million to $ 118.39 Million, with a yearly change of 5.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | NT$118.39 Million | -3.71% |
| 2024 | NT$122.95 Million | +4.55% |
| 2023 | NT$117.60 Million | -22.28% |
| 2022 | NT$151.31 Million | -- |
End of Day Market Cap According to Different Sources
On Jan 21st, 2026 the market cap of BRIM Biotechnology Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $118.39 Million USD |
| MoneyControl | $118.39 Million USD |
| MarketWatch | $118.39 Million USD |
| marketcap.company | $118.39 Million USD |
| Reuters | $118.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.